These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 39358333)

  • 1. Molecular and functional landscape of malignant serous effusions for precision oncology.
    Wegmann R; Bankel L; Festl Y; Lau K; Lee S; Arnold F; Cappelletti V; Fehr A; Picotti P; Dedes KJ; Franzen D; Lenggenhager D; Bode PK; Zoche M; Moch H; Britschgi C; Snijder B
    Nat Commun; 2024 Oct; 15(1):8544. PubMed ID: 39358333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
    Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
    Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
    Ianevski A; Nader K; Driva K; Senkowski W; Bulanova D; Moyano-Galceran L; Ruokoranta T; Kuusanmäki H; Ikonen N; Sergeev P; Vähä-Koskela M; Giri AK; Vähärautio A; Kontro M; Porkka K; Pitkänen E; Heckman CA; Wennerberg K; Aittokallio T
    Nat Commun; 2024 Oct; 15(1):8579. PubMed ID: 39362905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
    Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
    Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.
    Ruiz C; Kustermann S; Pietilae E; Vlajnic T; Baschiera B; Arabi L; Lorber T; Oeggerli M; Savic S; Obermann E; Singer T; Rothschild SI; Zippelius A; Roth AB; Bubendorf L
    PLoS One; 2016; 11(8):e0160807. PubMed ID: 27548442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
    Shee K; Wells JD; Jiang A; Miller TW
    PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
    Castven D; Becker D; Czauderna C; Wilhelm D; Andersen JB; Strand S; Hartmann M; Heilmann-Heimbach S; Roth W; Hartmann N; Straub BK; Mahn FL; Franck S; Pereira S; Haupts A; Vogel A; Wörns MA; Weinmann A; Heinrich S; Lang H; Thorgeirsson SS; Galle PR; Marquardt JU
    Int J Cancer; 2019 Jun; 144(11):2782-2794. PubMed ID: 30485423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
    Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
    [No Abstract]   [Full Text] [Related]  

  • 10. Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers.
    Nikas IP; Lim S; Im SA; Lee KH; Lee DW; Lee H; Ryu HS
    Pathobiology; 2024; 91(3):169-179. PubMed ID: 37816333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
    Yan T; Cui H; Zhou Y; Yang B; Kong P; Zhang Y; Liu Y; Wang B; Cheng Y; Li J; Guo S; Xu E; Liu H; Cheng C; Zhang L; Chen L; Zhuang X; Qian Y; Yang J; Ma Y; Li H; Wang F; Liu J; Liu X; Su D; Wang Y; Sun R; Guo S; Li Y; Cheng X; Liu Z; Zhan Q; Cui Y
    Nat Commun; 2019 Apr; 10(1):1670. PubMed ID: 30975989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preface on application of omics technologies in cancer biology and therapy.
    Georgakilas AG
    Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
    [No Abstract]   [Full Text] [Related]  

  • 13. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
    Tiran V; Stanzer S; Heitzer E; Meilinger M; Rossmann C; Lax S; Tsybrovskyy O; Dandachi N; Balic M
    PLoS One; 2017; 12(4):e0175223. PubMed ID: 28423035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimally Invasive, Maximally Effective: The Power of Precision Cytoanalysis on Effusion Samples-A Comprehensive Exploration from Traditional Methods to Innovative Approaches.
    Souza da Silva R; Schmitt F
    Surg Pathol Clin; 2024 Sep; 17(3):453-481. PubMed ID: 39129143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
    Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
    Nakamura IT; Ikegami M; Hasegawa N; Hayashi T; Ueno T; Kawazu M; Yagishita S; Goto Y; Shinno Y; Kojima Y; Takamochi K; Takahashi F; Takahashi K; Mano H; Kohsaka S
    Cancer Sci; 2021 May; 112(5):2006-2019. PubMed ID: 33484069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.